267 related articles for article (PubMed ID: 17875701)
1. Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling.
Kopitz C; Gerg M; Bandapalli OR; Ister D; Pennington CJ; Hauser S; Flechsig C; Krell HW; Antolovic D; Brew K; Nagase H; Stangl M; von Weyhern CW; Brücher BL; Brand K; Coussens LM; Edwards DR; Krüger A
Cancer Res; 2007 Sep; 67(18):8615-23. PubMed ID: 17875701
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10.
Schelter F; Grandl M; Seubert B; Schaten S; Hauser S; Gerg M; Boccaccio C; Comoglio P; Krüger A
Clin Exp Metastasis; 2011 Dec; 28(8):793-802. PubMed ID: 21789719
[TBL] [Abstract][Full Text] [Related]
3. Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1α.
Schelter F; Halbgewachs B; Bäumler P; Neu C; Görlach A; Schrötzlmair F; Krüger A
Clin Exp Metastasis; 2011 Feb; 28(2):91-9. PubMed ID: 21053058
[TBL] [Abstract][Full Text] [Related]
4. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.
Rapti M; Atkinson SJ; Lee MH; Trim A; Moss M; Murphy G
Biochem J; 2008 Apr; 411(2):433-9. PubMed ID: 18215140
[TBL] [Abstract][Full Text] [Related]
5. Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator.
Schrötzlmair F; Kopitz C; Halbgewachs B; Lu F; Algül H; Brünner N; Gänsbacher B; Krüger A
J Cell Mol Med; 2010 Dec; 14(12):2760-70. PubMed ID: 19863693
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-2, but not cystatin C, inhibits the prometastatic activity of tissue inhibitor of metalloproteinases-1 in the liver.
Kopitz C; Gerg M; Gansbacher B; Krüger A
Hum Gene Ther; 2008 Oct; 19(10):1039-49. PubMed ID: 18681831
[TBL] [Abstract][Full Text] [Related]
7. Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration.
Mohammed FF; Pennington CJ; Kassiri Z; Rubin JS; Soloway PD; Ruther U; Edwards DR; Khokha R
Hepatology; 2005 Apr; 41(4):857-67. PubMed ID: 15726641
[TBL] [Abstract][Full Text] [Related]
8. ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion.
Gangemi R; Amaro A; Gino A; Barisione G; Fabbi M; Pfeffer U; Brizzolara A; Queirolo P; Salvi S; Boccardo S; Gualco M; Spagnolo F; Jager MJ; Mosci C; Rossello A; Ferrini S
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1138-48. PubMed ID: 25124714
[TBL] [Abstract][Full Text] [Related]
9. Effects of hepatocyte growth factor on the expression of matrix metalloproteinases and their tissue inhibitors during the endometrial cancer invasion in a three-dimensional coculture.
Park YH; Ryu HS; Choi DS; Chang KH; Park DW; Min CK
Int J Gynecol Cancer; 2003; 13(1):53-60. PubMed ID: 12631221
[TBL] [Abstract][Full Text] [Related]
10. Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas.
Karan D; Lin FC; Bryan M; Ringel J; Moniaux N; Lin MF; Batra SK
Int J Oncol; 2003 Nov; 23(5):1365-71. PubMed ID: 14532978
[TBL] [Abstract][Full Text] [Related]
11. Invasion front-specific overexpression of tissue inhibitor of metalloproteinase-1 in liver metastases from colorectal cancer.
Kahlert C; Bandapalli OR; Schirmacher P; Weitz J; Brand K
Anticancer Res; 2008; 28(3A):1459-65. PubMed ID: 18630499
[TBL] [Abstract][Full Text] [Related]
12. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
13. ADAM10/17-dependent release of soluble c-Met correlates with hepatocellular damage.
Chalupský K; Kanchev I; Žbodáková O; Buryová H; Jiroušková M; Kořínek V; Gregor M; Sedláček R
Folia Biol (Praha); 2013; 59(2):76-86. PubMed ID: 23746173
[TBL] [Abstract][Full Text] [Related]
14. Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice.
Seubert B; Grünwald B; Kobuch J; Cui H; Schelter F; Schaten S; Siveke JT; Lim NH; Nagase H; Simonavicius N; Heikenwalder M; Reinheckel T; Sleeman JP; Janssen KP; Knolle PA; Krüger A
Hepatology; 2015 Jan; 61(1):238-48. PubMed ID: 25131778
[TBL] [Abstract][Full Text] [Related]
15. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
[TBL] [Abstract][Full Text] [Related]
16. Self-control of HGF regulation on human trophoblast cell invasion via enhancing c-Met receptor shedding by ADAM10 and ADAM17.
Yang Y; Wang Y; Zeng X; Ma XJ; Zhao Y; Qiao J; Cao B; Li YX; Ji L; Wang YL
J Clin Endocrinol Metab; 2012 Aug; 97(8):E1390-401. PubMed ID: 22689693
[TBL] [Abstract][Full Text] [Related]
17. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3.
Amour A; Knight CG; Webster A; Slocombe PM; Stephens PE; Knäuper V; Docherty AJ; Murphy G
FEBS Lett; 2000 May; 473(3):275-9. PubMed ID: 10818225
[TBL] [Abstract][Full Text] [Related]
18. Constitutive and induced CD44 shedding by ADAM-like proteases and membrane-type 1 matrix metalloproteinase.
Nakamura H; Suenaga N; Taniwaki K; Matsuki H; Yonezawa K; Fujii M; Okada Y; Seiki M
Cancer Res; 2004 Feb; 64(3):876-82. PubMed ID: 14871815
[TBL] [Abstract][Full Text] [Related]
19. A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor.
Schelter F; Kobuch J; Moss ML; Becherer JD; Comoglio PM; Boccaccio C; Krüger A
J Biol Chem; 2010 Aug; 285(34):26335-40. PubMed ID: 20554517
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy.
Fedak PW; Moravec CS; McCarthy PM; Altamentova SM; Wong AP; Skrtic M; Verma S; Weisel RD; Li RK
Circulation; 2006 Jan; 113(2):238-45. PubMed ID: 16401770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
